Breaking News

GSK Agrees to Acquire RAPT Therapeutics

The acquisition includes ozureprubart, an anti-immunoglobulin E monoclonal antibody currently in clinical development for prophylactic protection against food allergens.

Author Image

By: Charlie Sternberg

Associate Editor

GSK has entered a definitive agreement to acquire RAPT Therapeutics, a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases. The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in phase IIb clinical development for prophylactic protection against food allergens.  Tony Wood, Chief Scientific Officer, GSK said, “The addi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters